TP53 and neoplasm: Anti-PD-L1 treatment (Durvalumab 118.0 mg/kg IV two times) inhibited tumor growth in animals of experimental subgroups (Table 2) except both primary and relapsed p53 subtypes of NMIBC subgroups where T/C index was under the value of 50 at all checkpoints, and there was no difference in tumor-doubling time in comparison with relative vehicle control.